

Paul Brennan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1817005/publications.pdf>

Version: 2024-02-01

76
papers

5,149
citations

87888

38
h-index

98798

67
g-index

77
all docs

77
docs citations

77
times ranked

8470
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia. <i>Electronic Journal of Biotechnology</i> , 2021, 52, 1-12.	2.2	1
2	drawProteins: a Bioconductor/R package for reproducible and programmatic generation of protein schematics. <i>F1000Research</i> , 2018, 7, 1105.	1.6	41
3	Proteomics analysis of vesicles isolated from plasma and urine of prostate cancer patients using a multiplex, aptamer-based protein array. <i>Journal of Extracellular Vesicles</i> , 2016, 5, 31209.	12.2	58
4	Key Molecular Drivers of Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 593-606.	0.4	15
5	Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 3607-3617.	1.4	31
6	Proteomics-Based Strategies To Identify Proteins Relevant to Chronic Lymphocytic Leukemia. <i>Journal of Proteome Research</i> , 2014, 13, 5051-5062.	3.7	33
7	A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. <i>Oncotarget</i> , 2014, 5, 375-385.	1.8	73
8	CXCL12 Enhances CLL Cell and T-Cell Migration in a Dynamic Circulating Model of CLL That Can be Abrogated By the CXCR4 Antagonist ONO-7161. <i>Blood</i> , 2014, 124, 3293-3293.	1.4	0
9	Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2013, 98, 1930-1938.	3.5	64
10	Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2012, 158, 589-599.	2.5	45
11	Gene and protein responses of human lung tissue explants exposed to ambient particulate matter of different sizes. <i>Inhalation Toxicology</i> , 2012, 24, 966-975.	1.6	10
12	Reactive Oxygen Species and Mitochondrial Sensitivity to Oxidative Stress Determine Induction of Cancer Cell Death by p21. <i>Journal of Biological Chemistry</i> , 2012, 287, 9845-9854.	3.4	77
13	Defining the prognosis of early stage chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012, 156, 499-507.	2.5	44
14	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. <i>Journal of the National Cancer Institute</i> , 2011, 103, 250-263.	6.3	596
15	Proteomic profiling of human respiratory epithelia by iTRAQ reveals biomarkers of exposure and harm by tobacco smoke components. <i>Biomarkers</i> , 2011, 16, 567-576.	1.9	21
16	Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2. <i>Cell Proliferation</i> , 2011, 44, 380-390.	5.3	26
17	Co-operative Membrane Disruption Between Cell-penetrating Peptide and Cargo: Implications for the Therapeutic Use of the Bcl-2 Converter Peptide D-NuBCP-9-r8. <i>Molecular Therapy</i> , 2011, 19, 2124-2132.	8.2	20
18	Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. <i>Haematologica</i> , 2010, 95, 514-517.	3.5	10

#	ARTICLE	IF	CITATIONS
19	Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation. <i>Nucleic Acids Research</i> , 2010, 38, 2799-2812.	14.5	16
20	Proteomics Analysis of Bladder Cancer Exosomes. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 1324-1338.	3.8	343
21	Proteomics technologies for the global identification and quantification of proteins. <i>Advances in Protein Chemistry and Structural Biology</i> , 2010, 80, 1-44.	2.3	142
22	Bicarbonate-Dependent Serine/Threonine Protein Dephosphorylation in Capacitating Boar Spermatozoa. <i>Journal of Andrology</i> , 2010, 31, 393-405.	2.0	7
23	Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 763-769.	1.6	51
24	Soluble TLR2 Reduces Inflammation without Compromising Bacterial Clearance by Disrupting TLR2 Triggering. <i>Journal of Immunology</i> , 2009, 183, 506-517.	0.8	83
25	NF- κ B as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. <i>Future Oncology</i> , 2009, 5, 1027-1037.	2.4	31
26	STAT1 contributes to the maintenance of the latency III viral programme observed in Epstein-Barr virus-transformed B cells and their recognition by CD8+ T cells. <i>Journal of General Virology</i> , 2009, 90, 2239-2250.	2.9	12
27	Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD. <i>Journal of Controlled Release</i> , 2009, 140, 237-244.	9.9	60
28	Quantitative nuclear proteomics reveals new phenotypes altered in lymphoblastoid cells. <i>Proteomics - Clinical Applications</i> , 2009, 3, 359-369.	1.6	9
29	Polymorphisms in three base excision repair genes and breast cancer risk in Thai women. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 279-288.	2.5	65
30	Proliferation and interleukin-5 production by CD8 ⁺ CD57 ⁺ T cells. <i>European Journal of Immunology</i> , 2008, 38, 995-1000.	2.9	48
31	Duplication: most cases on database are innocent. <i>Nature</i> , 2008, 452, 29-29.	27.8	2
32	Targeting transcription factors for therapeutic benefit. <i>Molecular BioSystems</i> , 2008, 4, 909.	2.9	42
33	The Novel Nuclear Factor- κ B Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine. <i>Clinical Cancer Research</i> , 2008, 14, 8102-8111.	7.0	44
34	The NF- κ B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. <i>Blood</i> , 2008, 111, 4681-4689.	1.4	145
35	Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. <i>Blood</i> , 2008, 112, 3807-3817.	1.4	208
36	Pharmacological Inhibition of NF- κ B Underpins the Strong Synergy Between LC-1 and Fludarabine in Chronic Lymphocytic Leukaemia Cells. <i>Blood</i> , 2008, 112, 380-380.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Epstein-Barr virus induces a distinct form of DNA-bound STAT1 compared with that found in interferon-stimulated B lymphocytes. <i>Journal of General Virology</i> , 2007, 88, 1876-1886.	2.9	15
38	The XRCC3 Thr241Met polymorphism and breast cancer risk: a case-control study in a Thai population. <i>Biomarkers</i> , 2007, 12, 523-532.	1.9	29
39	Highly purified CD38+ and CD38 [~] sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. <i>Leukemia</i> , 2007, 21, 687-696.	7.2	48
40	Transcription Factor NF- κ B as a Biomarker for Disease Progression and Target for Treatment in Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2007, 110, 3091-3091.	1.4	0
41	CD38+ chronic lymphocytic leukaemia cells co-express high levels of ZAP-70 and are functionally distinct from their CD38 [~] counter-parts. <i>Leukemia</i> , 2006, 20, 743-744.	7.2	15
42	Epstein-Barr Virus Represses the FoxO1 Transcription Factor through Latent Membrane Protein 1 and Latent Membrane Protein 2A. <i>Journal of Virology</i> , 2006, 80, 11191-11199.	3.4	27
43	Expression of Glycosylphosphatidylinositol-Anchored CD59 on Target Cells Enhances Human NK Cell-Mediated Cytotoxicity. <i>Journal of Immunology</i> , 2006, 176, 2915-2923.	0.8	24
44	CD21 Expression Is Inversely Correlated with the Ability of CLL Cells To Induce Tyrosine Phosphorylation in Response to Anti-IgM. <i>Blood</i> , 2006, 108, 2806-2806.	1.4	0
45	Integrating Prognostic Markers and Cellular Signaling Identifies More Chronic Lymphocytic Leukemia Patients with Adverse Prognosis. <i>Blood</i> , 2006, 108, 2782-2782.	1.4	0
46	LY294002 and rapamycin co-operate to inhibit T-cell proliferation. <i>British Journal of Pharmacology</i> , 2005, 144, 791-800.	5.4	51
47	Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. <i>Arthritis and Rheumatism</i> , 2005, 52, 1287-1292.	6.7	58
48	Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF- κ B activation due to decreased surface expression. <i>FEBS Letters</i> , 2005, 579, 5193-5198.	2.8	46
49	Genetic Polymorphisms in the Base Excision Repair Pathway and Cancer Risk: A HuGE Review. <i>American Journal of Epidemiology</i> , 2005, 162, 925-942.	3.4	482
50	Susceptibility of B lymphocytes to adenovirus type 5 infection is dependent upon both coxsackie adenovirus receptor and α 5 integrin expression. <i>Journal of General Virology</i> , 2005, 86, 1669-1679.	2.9	13
51	ZAP-70 Expression Is More Predictive Than VH Gene Mutational Status of BCR-Mediated Tyrosine Phosphorylation, NF- κ B Activation and CLL Cell Survival. <i>Blood</i> , 2005, 106, 2942-2942.	1.4	0
52	The Novel Anti-Leukemic Agent LC-1, Is Preferentially Cytotoxic in CLL Cells Derived from Poor Prognostic Subsets. <i>Blood</i> , 2005, 106, 2981-2981.	1.4	0
53	CD22 Is a Functional Ligand for SH2 Domain-containing Protein-tyrosine Phosphatase-1 in Primary T Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 47783-47791.	3.4	21
54	Impaired Lymphoid Chemokine-Mediated Migration due to a Block on the Chemokine Receptor Switch in Human Cytomegalovirus-Infected Dendritic Cells. <i>Journal of Virology</i> , 2004, 78, 3046-3054.	3.4	58

#	ARTICLE	IF	CITATIONS
55	Analysis of human tumour necrosis factor receptor 1 dominant-negative mutants reveals a major region controlling cell surface expression. <i>FEBS Letters</i> , 2004, 570, 138-142.	2.8	7
56	Epstein-Barr virus LMP1 blocks p16INK4a/RB pathway by promoting nuclear export of E2F4/5. <i>Journal of Cell Biology</i> , 2003, 162, 173-183.	5.2	91
57	Latent Membrane Protein 1 Inhibits Epstein-Barr Virus Lytic Cycle Induction and Progress via Different Mechanisms. <i>Journal of Virology</i> , 2003, 77, 5000-5007.	3.4	58
58	Distinct Effects of STAT5 Activation on CD4+ and CD8+ T Cell Homeostasis: Development of CD4+CD25+ Regulatory T Cells versus CD8+ Memory T Cells. <i>Journal of Immunology</i> , 2003, 171, 5853-5864.	0.8	186
59	Epstein-Barr Virus Regulates STAT1 through Latent Membrane Protein 1. <i>Journal of Virology</i> , 2003, 77, 4439-4443.	3.4	28
60	Regulation of an Activated S6 Kinase 1 Variant Reveals a Novel Mammalian Target of Rapamycin Phosphorylation Site. <i>Journal of Biological Chemistry</i> , 2002, 277, 20104-20112.	3.4	160
61	Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. <i>Oncogene</i> , 2002, 21, 1263-1271.	5.9	55
62	Analysis of Interleukin-2 Signaling Using Affinity Precipitations and Polyacrylamide Gel Electrophoresis. , 2001, , 369-383.		0
63	Requirement for CD28 co-stimulation is lower in SHP-1-deficient T cells. <i>European Journal of Immunology</i> , 2001, 31, 3649-3658.	2.9	20
64	Signalling events regulating lymphoid growth and survival. <i>Seminars in Cancer Biology</i> , 2001, 11, 415-421.	9.6	17
65	Epstein-Barr Virus LMP-1 Natural Sequence Variants Differ in Their Potential To Activate Cellular Signaling Pathways. <i>Journal of Virology</i> , 2001, 75, 9129-9141.	3.4	65
66	Mechanism of Action of a Novel Latent Membrane Protein-1 Dominant Negative. <i>Journal of Biological Chemistry</i> , 2001, 276, 1195-1203.	3.4	49
67	Characterization of a CD40-Dominant Inhibitory Receptor Mutant. <i>Journal of Immunology</i> , 2001, 167, 6388-6393.	0.8	3
68	Characterization of Intercellular Adhesion Molecule-1 Regulation by Epstein-Barr Virus-encoded Latent Membrane Protein-1 Identifies Pathways That Cooperate with Nuclear Factor κ B to Activate Transcription. <i>Journal of Biological Chemistry</i> , 2001, 276, 984-992.	3.4	38
69	p70 ^{s6k} Integrates Phosphatidylinositol 3-Kinase and Rapamycin-Regulated Signals for E2F Regulation in T Lymphocytes. <i>Molecular and Cellular Biology</i> , 1999, 19, 4729-4738.	2.3	131
70	Involvement of phosphoinositide 3-kinase and Rac in membrane ruffling induced by IL-2 in T cells. <i>European Journal of Immunology</i> , 1998, 28, 1877-1885.	2.9	52
71	Inhibition of Nuclear Factor κ B by Direct Modification in Whole Cells—Mechanism of Action of Nordihydroguaiaritic Acid, Curcumin and Thiol Modifiers. <i>Biochemical Pharmacology</i> , 1998, 55, 965-973.	4.4	129
72	Involvement of phosphoinositide 3-kinase and Rac in membrane ruffling induced by IL-2 in T cells. <i>European Journal of Immunology</i> , 1998, 28, 1877-1885.	2.9	3

#	ARTICLE	IF	CITATIONS
73	Phosphatidylinositol 3-Kinase Couples the Interleukin-2 Receptor to the Cell Cycle Regulator E2F. <i>Immunity</i> , 1997, 7, 679-689.	14.3	383
74	2-mercaptoethanol restores the ability of nuclear factor $\hat{\text{I}}^{\text{B}}$ (NF $\hat{\text{I}}^{\text{B}}$) to bind DNA in nuclear extracts from interleukin 1-treated cells incubated with pyrrolidine dithiocarbamate (PDTC). Evidence for oxidation of glutathione in the mechanism of inhibition of NF $\hat{\text{I}}^{\text{B}}$ by PDTC. <i>Biochemical Journal</i> , 1996, 320, 975-981.	3.7	128
75	Effects of oxidants and antioxidants on nuclear factor $\hat{\text{I}}^{\text{B}}$ activation in three different cell lines: evidence against a universal hypothesis involving oxygen radicals. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1995, 1260, 167-175.	2.4	185
76	Data visualization with the programming language R. <i>Biochemist</i> , 0, , .	0.5	1